Clinical Trials › NCT05123703
Active, Not RecruitingPhase 3
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
Sponsored by Hoffmann-La Roche
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 188
Target enrollment
11
U.S. states
May 2022
Start date
Sep 2029
Expected completion
Interventions / Treatments
OcrelizumabOcrelizumab PlaceboFingolimodFingolimod Placebo
Conditions studied
Relapsing-Remitting Multiple Sclerosis
Where this trial is running (13 sites)
California2 sites
La Jolla · San Francisco
Ohio2 sites
Cleveland · Columbus
Colorado1 site
Aurora
District of Columbia1 site
Washington D.C.
Maryland1 site
Baltimore
Massachusetts1 site
Boston
Missouri1 site
St Louis
New Jersey1 site
New Brunswick
Pennsylvania1 site
Philadelphia
Texas1 site
Houston
Virginia1 site
Charlottesville
Participating MS centers on MS Buddy (9)
UC San Diego Health MS Program
La Jolla, CA
La Jolla, CA
Robert Wood Johnson Center for MS
New Brunswick, NJ
New Brunswick, NJ
John L. Trotter Multiple Sclerosis Center
Saint Louis, MO
Saint Louis, MO
UVA Multiple Sclerosis and Clinical Neuroimmunology Center
Charlottesville, VA
Charlottesville, VA
Johns Hopkins Multiple Sclerosis Center
Baltimore, MD
Baltimore, MD
Children's Hospital of Philadelphia Pediatric MS Clinic
Philadelphia, PA
Philadelphia, PA
Mellen Center for MS Treatment & Research
Cleveland, OH
Cleveland, OH
UCSF Multiple Sclerosis Center
San Francisco, CA
San Francisco, CA
MS centers in California
Compare treatment centers near a trial site — patient experience, providers, and care ratings.
View California centersMore Phase 3 trials
Browse all Phase 3 MS trialsCheck out the MS Buddy App
Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.
